In this episode, we look at the integration and development of artificial intelligence (AI) into medical technologies, or as the sector is commonly referred to: Medtech.
Countries today are racing to be the global leader in AI. Just earlier this month, President Donald Trump signed the “American A.I. Initiative,” an executive order meant to stimulate the development and regulation of artificial intelligence. Last year in the UK, Prime Minister Theresa May announced a plan to revolutionize how chronic diseases are diagnosed in the country by significantly increasing the use of data and AI.
With AI technology growing ever more sophisticated and governments leaning into its use in healthcare, investment in the sector seems likely to grow. However, there are more reservations about data privacy and concerns over implementation when it comes to incorporating AI in healthcare practices.
So, we turned to healthcare experts to help guide us through the opportunities, challenges, and serious investment opportunity that AI in Medtech presents.
We would like to extend a massive thank you to our amazing guests: Dr. Robert Pearl, author of Washington Post bestseller 'Mistreated'; Dr. Jenny Barnett, Chief Scientific Officer of Cambridge Cognition; and Ariel Beery, CEO of MobileODT.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Dave Wall, Managing Director of 88 Energy, said: "The decision by the Board to raise additional funds at this time was for several reasons, namely: unsolicited demand for investment at a premium to the most recent placement in September 2019; and a subsequent incremental increase in the well cost due to high grading of the quality of the evaluation program.”
Business leaders have welcomed what they call a clarification of the government's view that there would be "no alignment" with EU rules in a post-Brexit trade deal with the EU. Chancellor Sajid Javid said the UK would use the power to diverge from Europe only when it was in the interests of business.